Forma Therapeutics (Now Novo Nordisk)
Biotechnology ResearchMassachusetts, United States51-200 Employees
As of October, 2022, Forma Therapeutics has been acquired by Novo Nordisk.
Market Expansion Novo Nordisk continues to expand its manufacturing and operational footprint, as evidenced by recent facility expansions in Ireland. This growth indicates ongoing demand for biotechnology products and potential opportunities to supply supporting manufacturing technologies, automation, or facility management solutions.
Brand Visibility The company's strategic marketing initiatives, including high-profile Super Bowl commercials and global event participation, suggest a strong focus on brand awareness. This opens doors for engaging marketing technology, media planning, and digital advertising solutions to further amplify their campaigns.
Leadership & Strategy Recent executive hires in key US and product strategy roles highlight a focus on strengthening market position and portfolio management, presenting opportunities for consulting, analytical tools, and strategic planning services to support growth initiatives.
Legal and Compliance Novo Nordisk's active legal actions against competitors underscore the importance of compliance, legal services, and regulatory solutions, which could support their competitive positioning and risk management efforts.
Financial Growth With revenues between $25 million and $50 million and a funding amount of $100 million, the company shows promising growth potential. This signals opportunities in financial software, investment advisory, and partnership solutions to facilitate scaling and operational efficiency.
Forma Therapeutics (Now Novo Nordisk) uses 8 technology products and services including AppNexus, SiteCatalyst, Cart Functionality, and more. Explore Forma Therapeutics (Now Novo Nordisk)'s tech stack below.
| Forma Therapeutics (Now Novo Nordisk) Email Formats | Percentage |
| FLast@formatherapeutics.com | 89% |
| FirstLast@formatherapeutics.com | 8% |
| Last@formatherapeutics.com | 2% |
| First@formatherapeutics.com | 1% |
| FLast@novonordisk.com | 80% |
| First.Last@novonordisk.com | 11% |
| FirstL@novonordisk.com | 7% |
| LastF@novonordisk.com | 2% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
As of October, 2022, Forma Therapeutics has been acquired by Novo Nordisk.
Forma Therapeutics (Now Novo Nordisk) has raised a total of $100M of funding over 5 rounds. Their latest funding round was raised on Dec 19, 2019 in the amount of $100M.
Forma Therapeutics (Now Novo Nordisk)'s revenue is estimated to be in the range of $25M$50M
Forma Therapeutics (Now Novo Nordisk) has raised a total of $100M of funding over 5 rounds. Their latest funding round was raised on Dec 19, 2019 in the amount of $100M.
Forma Therapeutics (Now Novo Nordisk)'s revenue is estimated to be in the range of $25M$50M